Phenformin enhances the therapeutic effect of selumetinib in KRAS-mutant non-small cell lung cancer irrespective of LKB1 status

MEK inhibition is potentially valuable in targeting KRAS-mutant non-small cell lung cancer (NSCLC). Here, we analyzed whether concomitant LKB1 mutation alters sensitivity to the MEK inhibitor selumetinib, and whether the metabolism drug phenformin can enhance the therapeutic effect of selumetinib in...

詳細記述

保存先:
書誌詳細
出版年:Oncotarget
主要な著者: Zhang, Jun, Nannapaneni, Sreenivas, Wang, Dongsheng, Liu, Fakeng, Wang, Xu, Jin, Rui, Liu, Xiuju, Rahman, Mohammad Aminur, Peng, Xianghong, Qian, Guoqing, Chen, Zhuo G., Wong, Kwok-Kin, Khuri, Fadlo R., Zhou, Wei, Shin, Dong M.
フォーマット: Artigo
言語:Inglês
出版事項: Impact Journals LLC 2017
主題:
Research Paper
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC5601710/
https://ncbi.nlm.nih.gov/pubmed/28938614
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.19779
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料